EditorialEditorial
The Challenges of Quantifying the Risk of Serious Infection with Tumor Necrosis Factor Antagonist Therapy
JOHN LEOMBRUNO
The Journal of Rheumatology May 2010, 37 (5) 887-889; DOI: https://doi.org/10.3899/jrheum.100251
JOHN LEOMBRUNO
REFERENCES
- 1.↵
- 2.↵
- Carswell EA,
- Old LJ,
- Kassel RL,
- Green S,
- Fiore N,
- Williamson B
- 3.↵
- Maini RN,
- Breedveld FC,
- Kalden JR,
- Smolen JS,
- Davis D,
- Macfarlane JD,
- et al.
- 4.↵
- 5.↵
- 6.↵
- Maini R,
- St. Clair EW,
- Breedveld F,
- Furst D,
- Kalden J,
- Weisman M,
- et al.
- 7.↵
- Bongartz T,
- Sutton AJ,
- Sweeting MJ,
- Buchan I,
- Matteson EL,
- Montori V
- 8.↵
- Leombruno JP,
- Einarson TR,
- Keystone EC
- 9.↵
- Bernatsky S,
- Habel Y,
- Rahme E
- 10.↵
- Askling J,
- Fored CM,
- Brandt L,
- Baecklund E,
- Bertilsson L,
- Feltelius N,
- et al.
- 11.↵
- 12.↵
- Choquette D,
- Leombruno JP,
- Einarson TR
- 13.↵
- 14.↵
- Smitten AL,
- Choi HK,
- Hochberg MC,
- Suissa S,
- Simon TA,
- Testa MA,
- et al.
- 15.↵
- Breedveld FC,
- Weisman MH,
- Kavanaugh AF,
- Cohen SB,
- Pavelka K,
- van Vollenhoven R,
- et al.
In this issue
The Journal of Rheumatology
Vol. 37, Issue 5
1 May 2010
The Challenges of Quantifying the Risk of Serious Infection with Tumor Necrosis Factor Antagonist Therapy
JOHN LEOMBRUNO
The Journal of Rheumatology May 2010, 37 (5) 887-889; DOI: 10.3899/jrheum.100251